Beyond tumor necrosis factor and interleukin-12/23: The rise of interleukin-23 inhibitors in inflammatory bowel disease management.

Interleukin-23 (IL-23) has been identified as a key driver of chronic intestinal inflammation and treatment resistance, particularly in patients who have failed anti-tumor necrosis factor (TNF) therapy. Genetic studies and preclinical models have con…

Preview only. Read the full abstract at the source